Source: Andrew Wynn
SeaStar Medical Holding Corporation’s Q1 2026 Earnings Outlook
SeaStar Medical Holding Corporation (NASDAQ:ICU), a healthcare company in the commercial stage, is projected to report a net loss for Q1 2026. The expected loss, as per Wall Street’s projection, translates to an earnings per share (EPS) of -$0.83 and revenue of $437.5 thousand. EPS, a crucial metric for stock analysis, represents the portion of a company’s profit attributed to each outstanding share of common stock. A negative EPS, as in SeaStar Medical’s case, indicates a net loss for the given period, thus signifying that the company is not expected to be profitable this quarter.
The Profitability Challenges SeaStar Medical Faces
SeaStar Medical’s profitability metrics underscore the company’s recent struggles. The healthcare company, which is known for developing treatments for critically ill patients, exhibits a negative trailing price-to-earnings (P/E) ratio of -8.26 and an earnings yield of -12.11%. A negative P/E ratio happens when a company has lost money over the past year, demonstrating that it’s currently not profitable on a per-share basis. The earnings yield, another essential valuation metric, is also in the negative, further emphasizing the company’s financial losses.
Adding to the valuation perspective, the company’s price-to-sales ratio stands at 10.94. This ratio, which is used to compare a company’s stock price to its total sales, is another critical metric for assessing company performance from an investment point of view. However, the enterprise value-to-operating cash flow ratio of SeaStar Medical is negative, at -0.15, implying that the company is spending more cash on its business operations than it is generating.
The Stable Financial Structure of SeaStar Medical
Despite the challenges concerning profitability, SeaStar Medical has managed to maintain a robust financial structure. It boasts a low debt-to-equity ratio of 0.05, which shows that the company relies minimally on borrowed funds to finance its operations. This approach reduces the risk associated with excessive debt and can provide a safety cushion in times of economic downturns.
Further, the company’s current ratio, a liquidity ratio that measures a company’s ability to pay short-term and long-term obligations, stands at 3.63. This figure indicates that SeaStar Medical has a strong ability to repay its short-term liabilities with its short-term assets. In financial terms, this shows the company’s balance sheet strength and implies good financial health, which can be appealing to potential investors.
Conclusion
In conclusion, while SeaStar Medical is projected to report a net loss for Q1 2026, it is essential to consider the company’s strong balance sheet and relatively stable financial structure. While the negative earnings and profitability metrics raise concerns, the company’s low debt-to-equity ratio and high current ratio can be seen as indicators of financial resilience. This contrast between profitability challenges and financial stability presents a complex picture for potential investors, prompting the need for careful consideration of all factors involved.
As SeaStar Medical prepares to release its Q1 2026 financial results after the market closes on Wednesday, May 13, 2026, investors and analysts will undoubtedly be watching closely to see how the company navigates these challenges and capitalizes on its strengths.